Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney.
Renal cell carcinoma is the most common type of kidney cancer in adults. It occurs most often in men ages 50 to 70.
The exact cause is unknown.
The following may increase your risk of kidney cancer:
Other symptoms that can occur with this disease:
The health care provider will perform a physical exam. This may reveal:
The following tests may be done to see if the cancer has spread:
Surgery to remove of all or part of the kidney (nephrectomy) is recommended. This may include removing the bladder, surrounding tissues, or lymph nodes. A cure is unlikely unless all of the cancer is removed with surgery. But even if some cancer is left behind, patients can still benefit from surgery.
Hormone treatments may make the tumor smaller in some cases.
Chemotherapy is generally not effective for treating kidney cancer. The immune system medicine interleukin-2 (IL-2) may help some patients. Medicines that target the development of blood vessels that feed the tumor may be used to treat kidney cancer. Your doctor can tell you more.
Radiation therapy usually does not work for kidney cancer.
You can ease the stress of illness by joining a support group whose members share common experiences and problems.
Sometimes, both kidneys are involved. The cancer spreads easily, most often to the lungs and other organs. In about one-third of patients, the cancer has already spread (metastasized) at the time of diagnosis.
How well a patient does depends on how much the cancer has spread and how well treatment works. The survival rate is highest if the tumor is in the early stages and has not spread outside the kidney. If it has spread to the lymph nodes or to other organs, the survival rate is much lower.
Call your health care provider any time you see blood in the urine. Also call if you have any other symptoms of this disorder.
Stop smoking. Follow your health care provider's recommendations in the treatment of kidney disorders, especially those that may require dialysis.
Reviewed By: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.